Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06626113 · ClinicalTrials.gov registry record

Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension

A clinical trial of Obesity, sponsored by University of Kansas Medical Center.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT06626113: Recruiting study of Obesity, sponsored by University of Kansas Medical Center.

NCT06626113 is a study of Obesity that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06626113, a study of Obesity, is actively recruiting participants, sponsored by University of Kansas Medical Center.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance.

Conditions Studied

Interventions

  • DRUG ascorbic acid

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-08-01
Est. Completion 2027-09-01
University of Kansas Medical Center

408 total trials

What NCT06626113 shows while recruiting

NCT06626113 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which ascorbic acid is the first listed.

NCT06626113 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT06626113 about?

NCT06626113 is a clinical study titled "Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension". In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an in...

What is the current status of trial NCT06626113?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-08-01. Estimated completion is 2027-09-01.

What conditions does trial NCT06626113 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06626113?

The interventions under investigation include: ascorbic acid (DRUG).

Who is sponsoring clinical trial NCT06626113?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06626113 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06626113's enrollment target sits among peer trials

60 642nd of 1053 higher than 374 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06626113, the US trial registry maintained by the National Library of Medicine. NCT06626113 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.